New insights into the important roles of tumor cell-intrinsic PD-1

Hongmei Zheng, Yue Ning, Yuting Zhan, Sile Liu, Qiuyuan Wen, Songqing Fan

Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.

Corresponding author: Songqing Fan, Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. E-mail: songqingfan@csu.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

PD-1 (Programmed cell death protein-1) is mainly expressed in various immune cells, while its ligands PD-L1/PD-L2 (Programmed death ligand-1/Programmed death ligand-2) are mostly expressed in tumor cells. Generally, the binding of PD-L1/PD-L2 and PD-1 could lead to the tumor immune evasion. However, some recent studies showed that PD-1 could also be expressed in tumor cells and could activate mTOR (Mammalian Target of Rapamycin) or Hippo signaling pathway, therefore facilitating tumor proliferation independent of the immune system. While there was evidence that tumor cell-intrinsic PD-1 inhibited the activation of AKT and ERK1/2 pathways, thereby inhibiting tumor cell growth. Based on TCGA and CCLE database, we found that PD-1 was expressed in a variety of tumors and was associated with patient’s prognosis. Besides, we found that PD-1 may be involved in many carcinogenic signaling pathway on the basis of PD-1 gene enrichment analysis of cancer tissues and cancer cells. Our understanding of the tumor cell-intrinsic PD-1 function is still limited. This review is aimed at elaborating the potential effects of tumor cell-intrinsic PD-1 on carcinogenesis, providing a novel insight into the effects of anti-PD-1/PD-L1 immunotherapy, and helping to open a major epoch of combination therapy.

Key words: PD-L1; tumor cell-intrinsic PD-1; immunotherapy

Introduction

PD-1 is a CD28 superfamily protein encoded by gene PDCD1 on chromosome 2q37.3 [1, 2]. It is a cytomembrane protein composed of 268 amino acids with three domains, including transmembrane domain, immunoglobulin V-like domain and intracellular domain [3, 4]. PD-L1 and PD-L2, two ligands of PD-1, pertain to B7 protein family, which are composed of 290 amino acids and 273 amino acids, respectively [2]. It is generally believed that PD-L1/PD-L2 is mainly expressed in tumor and antigen-presenting cells, while PD-1 is often expressed in various immune cells, such as T lymphocytes, B lymphocytes and myeloid dendritic cells [5-7]. In tumor microenvironment, the binding of PD-L1 and PD-1 negatively regulates T cell function and inhibits the production of cytokines, thus promoting tumor immune escape [8]. Pathways P13K/Akt and MAPK (Mitogen-activated protein kinase) as well as transcriptional factors STAT3, HIF-1 and NF-kB have been shown to facilitate the up-regulation of PD-L1 [9]. TGF-β1 (Transforming growth factor-beta 1) increases the PD-1 expression of antigen-specific T cell through Smad3 [10]. Anti-PD-L1/anti-PD-1 drugs can restore the effective immune response of immune cells to tumor, which have significantly improved the prognosis of patients with solid tumors. However, only a few patients have achieved long-term curative effect, and many patients eventually relapse due to drug resistance [11]. Recent studies have shown that PD-1 could also be expressed in tumor cells [12], but its function remains to be further studied. Therefore, it is urgent and necessary to investigate the specific mechanisms of PD-1/PD-L1 axis, especially the function of tumor cell-intrinsic PD-1 independent of adaptive immunity. This review elaborates the potential effects of tumor cell-intrinsic PD-1 on carcinogenesis and its clinical significance.
The structure and regulation of PD-1

PD-1 was first found in mouse apoptotic T cells in 1992. It is an inhibitory costimulatory molecule, also known as CD279, encoded by gene PDCD1 on chromosome 2q37.3 [1]. PD-1 is a transmembrane protein, which consists of 268 amino acids with a relative molecular weight of 50-55 KDa. It consists of three parts: extracellular IgV-like domain, hydrophobic transmembrane domain and intracellular domain, including immunoreceptor tyrosine-based switch motif (ITSM) and immunoreceptor tyrosine-based inhibitory motif (ITIM) which are important structural sites for PD-1 to exert immunosuppressive effect [13, 14]. PD-1 is mainly found on the surface of B cell, activated CD4+, CD8+ T cell and monocytes [5-7]. The PD-1 expression of T cell surface could be induced by some cytokines such as IL-7, IL-15 and IL-21 [15]. miRNAs are a particular type of non-coding single-stranded RNA molecules encoded by endogenous genes and have about 22 nucleotides in length, which inhibit mRNA translation or directly degrade it by completely or partially pairing with complementary sequences on mRNA 3'UTR of the target gene [16]. It has been found that the interaction of miR-4717 and PD-1 3'UTR single nucleotide polymorphism rs10204525 could down-regulate the expression of PD-1, affect the progress of chronic HBV infection, and change the immune status of the body at the same time [17]. miR-28 and miR-138 have also been shown to inhibit the expression of PD-1 [18, 19]. Besides, TGF-β1 could enhance PD-1 expression on TILs (tumor infiltrating lymphocytes) through Smad3, thereby inducing tumor escape from host immune responses [10].

The PD-1 signaling pathway

The complete immune systems could identify and eliminate tumor cells through immune examination, but tumors can adapt to and evade these defense mechanisms [20, 21]. The combination of PD-L1 and PD-1 can phosphorylate the tyrosine in ITSM domain of PD-1, recruit SHP-1 (Src homology 2 domain-containing phosphatases-1) and SHP-2, and inhibit the activation of PI3K/Akt, which ultimately weakens the activation and proliferation of T lymphocytes, inhibits cytokine secretion and induces apoptosis of T lymphocytes [22, 23]. PI3K/Akt signal is a significant downstream pathway of PD-1. PD-1 can induce PTEN phosphatase activity, thus inhibiting PI3K/Akt pathway [24-26]. PD-1 also prevents T cell from expressing PI3K-dependent anti-apoptotic protein Bcl-XL [27]. Besides, PD-1 can block Ras/MEK/ERK pathway, thereby regulating cell cycle molecules and halting the proliferation of T cell [28]. Interestingly, PD-1 inhibits PI3K/Akt pathway in a few minutes, while blocking Ras/MEK/ERK pathway takes several hours [29]. In addition, PD-1 can hinder phosphorylation of ZAP70 and activation of PKC-θ, which are critical for T-cell activation, and prevent the development of effector T cells by promoting fatty acid oxidation and inhibiting glycolysis [30, 31]. Also, PD-1/PD-L1 axis can activate and transmit anti-Fas apoptotic signal, affect the differentiation of dendritic cells and T lymphocytes, and activate the cytolytic effect of innate anti-CD8+ T lymphocytes [32]. Furthermore, PD-1/PD-L1 axis can promote the development of iTreg (induced regulatory T) cell and increase Foxp3 expression on its surface, induce the differentiation of CD4+CD25+ Foxp3+Treg and maintain its immunosuppressive function, thereby indirectly inhibiting T cells proliferation and promoting tumor immune evasion [33].

Expression of PD-1 in cancer and its prognostic significance

It is widely believed that PD-1 is often expressed in activated CD4+ and CD8+ T cells, B cells, dendritic cells (DCs) and monocytes [5-7]. In the tumor microenvironemnt, PD-1 is mainly expressed on the surface tumor-infiltrating lymphocytes. It has been demonstrated that PD-1 and AFAPI-AS1 (Actin filament-associated protein 1 antisense RNA 1) were co-expressed in the infiltrating lymphocytes of nasopharyngeal carcinoma tissues and patients with co-expression of AFAPI-AS1 and PD-1 had poor survival [34]. Besides, it was confirmed by Li et al. that PD-1 of lymphocytes was an independent prognostic factor both for DFS and OS of colorectal cancer patients [35]. Interestingly, PD-1 positivity of tumor-infiltrating lymphocytes was also an independent worse prognosis factor in patients with upper tract urothelial carcinoma [36].

However, some emerging studies have shown the expression and functions of PD-1 in tumor cells and tissues [12]. The expression of PD-1 protein in different tissues from THE HUMAN PROTEIN ATLAS (https://www.proteinatlas.org/) was shown Figure 1. Li and his colleagues found that liver cancer cells and tissues could express PD-1, and hepatocellular carcinoma patients with low PD-1 expression had a higher survival rate and disease-free survival [37]. In addition, there was also the expression of tumor cell-intrinsic PD-1 in NSCLC [38]. Most notably, it has been demonstrated that PD-1 was also localized in cytoplasm and cell membrane of the pancreatic ductal adenocarcinoma cells and its expression was associated with OS [39]. The main driver of tumor cell-intrinsic PD-1 expression remains...
unclear, but epigenetic alteration, gene amplification and posttranscriptional modification may be involved. In conclusion, PD-1 is expressed not only on tumor infiltrating lymphocytes, but also on tumor cells, which has shed new light on the precision treatment of tumors.

Besides, in order to further expound the PD-1 mRNA level and its prognostic significance in various cancers, we used UALCAN website (http://ualcan.path.uab.edu/) to analyse TCGA gene data. In our results, we found that mRNA expression of PD-1 (PDCD1) was evidently higher in lung adenocarcinoma/squamous cell carcinoma, hepatocellular carcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma and renal clear cell carcinoma than that in normal control (Figure 2; all \( P < 0.05 \)). In addition, mRNA expression of PD-1 (PDCD1) was also elevated in metastasis cutaneous melanoma than that in primary cutaneous melanoma \((P<0.0001)\). But, we also found that mRNA expression of PD-1 (PDCD1) was higher in normal control than that in thyroid carcinoma \((P<0.05)\) but no different was found between pancreatic adenocarcinoma and its normal control \((P>0.05)\). Furthermore, the results showed that high PD-1 (PDCD1) mRNA level patients had poor prognosis in acute myeloid leukemia, cutaneous melanoma and renal carcinoma (Figure 3; all \( P < 0.05 \)), but had no impact on pancreatic carcinoma, hepatocellular carcinoma, lung cancer and breast invasive carcinoma (all \( P > 0.05 \)).

The roles of tumor cell-intrinsic PD-1

**Tumor cell-intrinsic PD-1 activates mTOR pathway**

mTOR, a considerably conserved serine/threonine protein kinase, is one of the important substrates downstream of Akt [40], which exists in the form of mTORC1 and mTORC2 complexes [41]. mTORC1 consists of mTOR, raptor and mLST8 and regulates the biosynthesis of intracellular translation elements [42]. mTOR signaling pathway is key to gene translation, which ultimately regulates cell growth and survival [43]. Activated mTORC1 can phosphorylate its downstream 4E-BP1 and S6K1. Phosphorylated 4E-BP1 dissociates from eIF4E, makes eIF4E free and promotes the transcription of proto-oncogenes such as c-myc and HIF-1α [44, 45]. While phosphorylated S6K1 can continue to phosphorylate ribosomal protein S6, eIF4B and other targets related to the translation of mRNA [46]. In hepatocellular carcinoma, tumor cell-intrinsic PD-1 can active mTOR pathway, which binds to the downstream target molecules S6 and eIF4E and promotes their phosphorylation, thus promoting tumor progression independently from specific immunity [37]. The findings put forward the possibility that PD-1 may be associated with cyclin D1 in tumor development by the regulation of p-eIF4E and suppress tumor necrosis factor-related apoptosis by regulating S6 [37]. Intriguingly, melanoma-expressed PD-1 activates mTOR signaling and promotes tumorigenesis by interacting with PD-L1 [47].

![Figure 1. Expression of PD-1 (PDCD1) protein in various cancer tissues from THE HUMAN PROTEIN ATLAS. The expression of PD-1 protein in renal cancer (A), liver cancer (B), skin cancer (C), pancreatic cancer (D), testis cancer (E) and urothelial cancer (F).](http://www.ijbs.com)
Figure 2. mRNA expression of PD-1 (PDCD1) in various cancer tissues of TCGA database. mRNA expression of PDCD1 in lung adenocarcinoma (A), lung squamous cell carcinoma (B), hepatocellular carcinoma (C), esophageal carcinoma (D), head and neck squamous cell carcinoma (E), breast invasive carcinoma (F), renal clear cell carcinoma (G), cutaneous melanoma (H), thyroid carcinoma (I) and pancreatic adenocarcinoma (J).
Figure 3. Effect of PD-1 (PDCD1) on prognosis in different cancer patients of TCGA database. Effect of PDCD1 expression level on prognosis in patients with acute myeloid leukemia (A), cutaneous melanoma (B), renal papillary cell carcinoma (C), renal clear cell carcinoma (D), pancreatic carcinoma (E), hepatocellular carcinoma (F), lung adenocarcinoma (G), lung squamous cell carcinoma (H), breast invasive carcinoma (I), and head and neck squamous cell carcinoma (J).
Tumor cell-intrinsic PD-1 activates Hippo pathway

Hippo signaling pathway regulates organ size through suppressing cell proliferation and increasing apoptosis and plays a significant role in development and homeostasis. Its main members include MST1/2, LATS1/2, SAV1, MOB1 and downstream effector molecules YAP and TAZ in mammals [48, 49]. Dysregulation of this pathway is also related to the development of cancers. When Hippo pathway is activated, MST1/2 kinase binds to its ligand protein Sav and activates Sav. Then phosphorylated LATS1/2 kinase and MOB1 protein increase LATS/MOB1 complex and activate LATS1/2 kinase. Finally, activated LATS1/2 kinase phosphorylates and inactivates YAP and TAZ [50]. On the contrary, dephosphorylated YAP/TAZ translocates into the nucleus, thereby induces the expression of target gene through binding to transcription factors, such as TEA domain family members [51, 52]. In pancreatic cancer, tumor cell-intrinsic PD-1 interacts with MOB1 and decreases MOB1 phosphorylation, thereby suppressing the phosphorylation of LATS1 and inactivating LATS1, which inhibits YAP phosphorylation and accumulates YAP protein. And the accumulated YAP protein binds to TEDA and translocates into the nucleus, activating downstream genes of Hippo pathway, such as CYR61 and CTGF, which facilitates tumor proliferation independent of the immune system [39].

Tumor cell-intrinsic PD-1 inhibits AKT and ERK1/2 pathways

p-AKT (phosphorylated protein kinase B) is a key molecule in activating PI3K/Akt signaling pathway that plays a crucial role in tumor development and progression [53]. ERK1/2 (extracellular regulated protein kinase 1/2) is a member of MAPK (mitogen activated protein kinase) family. p-ERK1/2 (phosphorylated ERK1/2) can transfer to the nucleus, regulate the activity of transcription factors, and ultimately change the metabolism and function of cells and participate in forming malignant tumor cells [54-56]. In lung cancer, tumor cell-intrinsic PD-1 is a tumor suppressor that inhibits the activation of AKT and ERK1/2 and thereby inhibits tumor cell growth [57]. These evidences suggest that tumor cell-intrinsic PD-1 plays different roles in various tumors.

PD-1 Gene enrichment analysis

Enrichment Analysis of Cancer Tissues

Sample data of liver cancer, melanoma, lung cancer and pancreatic cancer were downloaded from TCGA database, which were grouped into high and low expression on the basis of mean value of PD-1 (PDCD1) level. The differentially expressed genes were analyzed by analysis software DECenter (|logFC|>1, P<0.05). The GO and KEGG analysis about PDCD1 gene were analyzed by online DAVID website (https://david.ncifcrf.gov/). The results showed that in liver cancer, there were 1175 differentially expressed genes, including 1067 up-regulation and 108 down-regulation. KEGG analysis found they were chiefly related to signaling pathways, such as PI3K-Akt, Chemokine, NF-kappa B, Jak-STAT, HIF-1, VEGF and TNF (Figure 4A). In melanoma, we found 779 differentially expressed genes, including 762 up-regulation and 17 down-regulation. KEGG found they were associated with signaling pathways, such as Chemokine, Jak-STAT, NF-kappa B, Toll-like receptor, Rap1, TNF and NOD-like receptor (Figure 4B). In lung cancer, there were 741 differently expressed genes, including 52 up-regulation and 689 down-regulation. KEGG indicated they were related to signaling pathways, such as Chemokine, NF-kappa B, Jak-STAT, Rap1, TNF and Toll-like receptor (Figure 4C). In pancreatic cancer, there were 981 differentially expressed genes, including 23 up-regulation and 958 down-regulation. KEGG found they were related to signaling pathways, such as Chemokine, NF-kappa B, Jak-STAT, Toll-like receptor, PI3K-Akt and Ras (Figure 4D). GO analysis of PD-1 in these four cancers showed that differentially expressed genes were mainly involved in molecular functions related to immune response, signal transduction, cell adhesion, positive regulation of ERK1 and ERK2 cascade and GTPase activity.

Enrichment Analysis of Cancer Cells

Data from TCGA database may not precisely reflect the PD-1 (PDCD1) level of tumor cells, because there are a lot of infiltrating immune cells in tumor tissues. Therefore, we also analyzed PD-1 (PDCD1) expression in CCLE dataset to exclude the effect of PD-1 on immune cells. Data of PD-1 mRNA in lung cancer cells, liver cancer cells, melanoma cells and pancreatic cancer cells were grouped into high and low expression on the basis of mean value of PD-1. The differentially expressed genes were analyzed by software DECenter (|logFC|>0.1, P<0.05). The GO and KEGG analysis about PD-1 were analyzed by online DAVID website. The results showed that in liver cancer, there were 142 differentially expressed genes, including 137 up-regulation and 5 down-regulation. GO enrichment analysis showed they were relative to positive regulation of apoptotic process and G-protein coupled receptor signaling.
pathway. KEGG analysis found they were chiefly related to signaling pathways, such as mTOR, folate biosynthesis and protein digestion and absorption (Figure 5A). In melanoma, we found 165 differentially expressed genes, all of which were up-regulated genes. GO enrichment analysis indicated these genes were relative to metabolic process, intracellular signal transduction and retinoic acid metabolic process. KEGG analysis found they were connected with signal pathways, like drug metabolism-cytochrome P450, metabolic pathways and chemical carcinogenesis (Figure 5B). In lung cancer, there were 469 differentially expressed genes, including 419 up-regulation and 50 down-regulation. GO enrichment analysis indicated these genes were relative to intracellular signal transduction, positive regulation of transcription from RNA polymerase II promoter, angiogenesis and integrin-mediated signaling pathway. KEGG analysis indicated they were connected with retinol metabolism, metabolic pathways and proteoglycans in cancer (Figure 5C). In pancreatic cancer, there were 1129 differentially expressed genes, including 689 up-regulation and 440 down-regulation. GO enrichment analysis showed that they were relative to apoptotic process, response to drug, cell-cell adhesion, protein folding and metabolic process. KEGG analysis indicated they were connected with metabolic pathways, ECM-receptor interaction, retinol metabolism and chemical carcinogenesis (Figure 5D).

**Combination therapy based on PD-1 inhibitors**

Currently, cancer immunotherapy is changing the clinical treatment of various cancers. PD-1 antibodies, such as, Nivolumab (Opdivo) and cemiplimab (Libtayo) and PD-L1 antibodies, like durvalumab and Atezolizumab, have been approved to be used in clinical application [58]. Anti-PD-L1/PD-1 antibodies could relieve immunosuppression of T cells by binding with PD-1/PD-L1, thereby recovering T cell ability to kill tumor cells and normalizing the immune system [59, 60]. However, only a proportion of patients could be beneficial from this immunotherapy with low response rate. More and more researches have shown that the combination of anti-PD-L1/PD-1 antibodies with other therapies may achieve better clinical results [58]. CTLA-4 is different from PD-1 in inhibiting the activation of T cell [61]. Greater clinical benefits can be obtained when combined with CTLA-4 and PD-1 in...
the treatment of metastatic melanoma and lung cancer [62]. Besides, the combination of anti-PD-L1/PD-1 blockade with chemoradiotherapy has also shown promising results, especially in NSCLC patients, who have achieved higher overall efficacy and survival rate in the combined treatment [63]. In addition to the tumor itself, gastrointestinal microbiome may also affect the response to immunotherapy. Some remarkable studies have reported that good gut bacteria were necessary for patient’s response to anti-PD-1 therapy and thereby the combination with anti-microbiome modulation may be beneficial for immunotherapy [64, 65]. Because PD-1 can also be expressed on tumor cells and activate some carcinogenic signaling pathway, many combination therapies based on this are also under development. For example, researchers find that in pancreatic ductal adenocarcinoma (PDAC), tumor cell-intrinsic PD-1 can facilitate tumor growth through hippo pathway and PD-1 checkpoint blockade combined with hippo pathway inhibitors can enhance its antitumor effect [39]. Results from recent evidences demonstrate that tumor cell-intrinsic PD-1 can activate mTOR signal in liver cancer and combination therapy targeting mTOR pathways and PD-1 may have a better clinical efficacy [37]. So far, there are many clinical studies about combination therapy based on PD-1 inhibitor Nivolumab, which is shown in Table 1.

Taken together, further clarifying the combination anti-PD-L1/PD-1 with other therapies will have synergistic effects and improve the clinical results of multiple cancer patients.

Conclusion

For a long time, it has been widely believed that PD-1 is only expressed on immune cells and PD-L1 is mainly on tumor cells. With more and more in-depth researches, PD-1 on tumor cells has been revealed. Recent studies indicated PD-1 was found in liver cancer, lung cancer, melanoma and pancreatic cancer cells. Also, researchers found that tumor cell-intrinsic PD-1 may activate mTOR or Hippo signaling pathway, therefore facilitating tumor proliferation independent from immune system. However, tumor cell-intrinsic PD-1 can also inhibit the activation of AKT and ERK1/2 pathways, thereby inhibiting tumor cell growth. We used TCGA and CCLE database for enrichment analysis and found that PD-1 may be involved in many carcinogenic signaling pathway. Although there are increasing studies aimed at elucidating the roles of PD-1 and its clinical significance in tumor cells, our understanding about it is still limited. In the future, further researches on tumor cell-intrinsic PD-1 might offer a novel insight into the effects of anti-PD-L1/PD-1 immunotherapy, and help to open a major era of combination therapy.
Table 1. Clinical trials of Nivolumab-based combination therapy

| Combination drug                  | Clinical trial ID  | Phase   | Study title                                                                 |
|-----------------------------------|--------------------|---------|----------------------------------------------------------------------------|
| Nivolumab+Azacitidine             | NCT04128020        | Phase 1 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia (Avida-3) |
| Nivolumab+Avadomide (CC-122)      | NCT0334623         | Phase 2 | Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma       |
| Nivolumab+Testosterone cypionate  | NCT03554317        | Phase 1 | COMBination of Bipolar Androgen Therapy and Nivolumab (COMBAT-CRPC)         |
| Nivolumab+Tivozanib               | NCT03136207        | Phase 1 | 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC   |
| Nivolumab+Ipillarumab             | NCT03651271        | Phase 2 | Treatment With Nivolumab and Ipillarumab or Nivolumab Alone according to the Percentage of Tumor CD8 Cells in Advanced Metastatic Cancer |
| Nivolumab+Ramucirumab             | NCT03502746        | Phase 2 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Metastasized Pancreatic Ductal Adenocarcinoma (ROCC-1) |
| Nivolumab+Ipilimumab              | NCT02799910        | Phase 2 | NIMBUS: Nivolum Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer |
| Nivolumab+Regorafenib             | NCT03712943        | Phase 1 | Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer (SKYRASIS) |
| Nivolumab+Cabozantinib            | NCT04197310        | Phase 2 | Cabozantinib and Nivolumab for Carcoid Tumors                               |
| Nivolumab+Anlotinib Hydrochloride | NCT04503967        | Phase 2 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer (OASBS) |
| Nivolumab+Pemtrexed               | NCT04107103        | Phase 2 | Nivolumab Plus Pemtrexed for Head and Neck-Squamous Cell Carcinoma (NivoPlus) |
| Nivolumab+HF10                    | NCT0259425         | Phase 2 | Neadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIb, IIIC, PVM1a Melanoma |
| Nivolumab+HBI-8000                | NCT02718066        | Phase 1 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer |
| Nivolumab+Copanlisib             | NCT03884998        | Phase 2 | Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin’s Lymphoma |
| Nivolumab+APX005M                 | NCT03132783        | Phase 2 | CD40 Agonistic Antibody APX005M in Combination With Nivolumab |
| Nivolumab+ACY-241                 | NCT02635061        | Phase 1 | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer |

Abbreviations

PD-1: programmed cell death protein-1; PD-L1: programmed death ligand-1; PD-L2: programmed death ligand-2; mTOR: Mammalian Target of Rapamycin; TCGA: The Cancer Genome Atlas; MAPK: mitogen-activated protein kinase; STAT3: Signal Transducer and Activator of Transcription 3; HIF-1: hypoxia inducible factor-1; NF-kB: nuclear factor kappa-B; TGF-β1: transforming growth factor-beta 1; ITSM: immunoreceptor tyrosine-based switch motif; ITIM: immunoreceptor tyrosine-based inhibitory motif; SHP-1: Src homology 2 domain-containing phosphatases-1; iTrg: induced regulatory T; DCs: dendritic cells; NKT: natural killer T cells; AFAPI-AS1: actin filament-associated protein 1 antisense RNA 1; NPC: nasopharyngeal carcinoma; OS: overall survival; DFS: disease free survival; NSCLC: non-small cell lung cancer; mLST8: mammalian ortholog of LST8; 4E-BP1: eukaryotic initiation factor 4E-binding protein 1; S6K1: p70 ribosomal protein S6 kinase B1; eIF4E: eukaryotic initiation factor 4E; eIF4B: eukaryotic initiation factor 4B; MST1/2: mammalian STE20-like protein kinase 1/2; LATS1/2: large tumor suppressor 1/2; SAV1: Salvador family WW domain-containing protein 1; MOB1: MOB kinase activator 1; YAP: Yes-associated protein; TAZ: transcriptional coactivator with a PDZ-binding domain; TEADs: TEA domain family members; CYR61: cysteine-rich angiogenic inducer 61; CTGF: connective tissue growth factor; CCLE: Cancer Cell Line Encyclopedia; CTLA-4: Cytotoxic T lymphocyte associated antigen-4; PDAC: Pancreatic ductal adenocarcinoma.

Acknowledgements

Funding

This work was supported by the National Natural Science Foundation of China (No: 81773218, 81972838 and 81703009) and The Natural Science Foundation of Hunan Province (No: 2017JJ3457).

Availability of data and materials

Data were obtained from the TCGA and CCLE database, UALCAN website (http://ualcan.path.uab.edu/), THE HUMAN PROTEIN ATLAS (https://www.proteinatlas.org/) and the DAVID website (https://david.ncifcrf.gov/).

Author Contributions

Hongmei zheng wrote the manuscript and created the figures and the table. The other authors read and approved the final manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel immunoreceptor, by human glial cells. Int Immunol. 1995; 7: 1129-36.
2. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel immunoreceptor, by human glial cells. Int Immunol. 1995; 7: 1129-36.
3. Daeron M, Jaeger S, Du Pasquier L, et al. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev. 2008; 224: 11-43.
4. El FA, Voisin T, Rouyer-Fessard C, et al. Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orxex receptor OX1R-driven apoptosis. FASEB J. 2009; 23: 4069-80.
Saunders PA, Hendrycks VR, Lidinsky WA, et al. PD-L2:PD-1 inhibit T cell proliferation. Sci Signal. 2012; 5:a46.

Sidorenko SP, Clark EA. The dual-function CD150 receptor subfamily: roles in T cell proliferation, cytokine production, and differentiation. Int Immunol. 2007; 19: 813-24.

Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates resistance to anti-PD-1 immunotherapy in melanoma patients. Science. 2018; 359: 1350-5.

Page DB, Blasco MT, Llorente A, et al. ERK1/2 Signaling Induces From Enhancement to Normalization. Cell. 2018; 175: 313-26.

Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2017; 170: 1-13.

Wei SC, Levine JH, Cogdill AP, et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2019; 15: 1111-22.

Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015; 125: 3384-91.

Matsuzaki K, Koizumi T, Naito M, et al. MET Antagonists Induce Tumor Cell Death through Apoptosis by Inhibiting O-GlcNAcylation. Cancer Res. 2020; 80: 4668-80.

Levine JH, Cogdill AP, et al. Targeted Inhibition of Rictor/mTORC2 in Cancer: A New Era after Rapamycin. Cancer Res. 2018; 78: 5363-55.
65. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018; 359: 104-8.